MOESM2 of Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis

Additional file 2: Figure S2. Sensitivity analysis of the long-term prognostic outcomes of anti-PD-1/PD-L1 therapy (Non-smoker vs. Smoker).